Regulation of cytokine release and anti-tumor effect of anti-CD20 CAR modified expanded natural killer cells by ALT-803, an Il-15 superagonist

被引：0
|
作者：
Chu, Yaya [1 ]
Su, Nang Kham [1 ]
Hamby, Carl [2 ]
Jeng, Emily K. [3 ]
Alter, Sarah [4 ]
Barth, Mathew [5 ]
Wong, Hing C. [3 ]
Lee, Dean A. [6 ]
Cairo, Mitchell S. [1 ,7 ,8 ,9 ,10 ]
机构：
[1] New York Med Coll, Pediat, Valhalla, NY 10595 USA
[2] New York Med Coll, Microbiol & Immunol, Valhalla, NY 10595 USA
[3] HCW Biol, Miramar, FL USA
[4] Altor BioSci, Miramar, FL USA
[5] SUNY Buffalo, Dept Pediat, Buffalo, NY USA
[6] Nationwide Childrens Hosp, Hem Onc BMT, Columbus, OH USA
[7] New York Med Coll, Maria Fareri Childrens Hosp, Med, Valhalla, NY 10595 USA
[8] New York Med Coll, Maria Fareri Childrens Hosp, Pathol, Valhalla, NY 10595 USA
[9] New York Med Coll, Maria Fareri Childrens Hosp, Microbiol & Immunol, Valhalla, NY 10595 USA
[10] New York Med Coll, Maria Fareri Childrens Hosp, Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
89
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [31] IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
    Kim, Peter S.
    Kwilas, Anna R.
    Xu, Wenxin
    Alter, Sarah
    Jeng, Emily K.
    Wong, Hing C.
    Schlom, Jeffrey
    Hodge, James W.
    ONCOTARGET, 2016, 7 (13) : 16130 - 16145
  • [32] Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo
    Silvestre, Renata Nacasaki
    Eitler, Jiri
    de Azevedo, Julia Teixeira Cottas
    Tirapelle, Mariane Cariati
    Fantacini, Daianne Maciely Carvalho
    de Souza, Lucas Eduardo Botelho
    Swiech, Kamilla
    Covas, Dimas Tadeu
    Calado, Rodrigo T.
    Montero, Paola Ortiz
    Malmegrim, Kelen Cristina Ribeiro
    Figueiredo, Marxa L.
    Tonn, Torsten
    Picanco-Castro, Virginia
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
    Chu, Yaya
    Hochberg, Jessica
    Yahr, Ashlin
    Ayello, Janet
    van de Ven, Carmella
    Barth, Matthew
    Czuczman, Myron
    Cairo, Mitchell S.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (04) : 333 - 344
  • [34] First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
    Fehniger, Todd A.
    Hess, Brian T.
    Bachanova, Veronika
    Becker-Hapak, Michelle
    McClain, Ethan
    Berrien-Elliott, Melissa
    Wagner, Julia
    Bartlett, Nancy L.
    Kahl, Brad
    Mehta-Shah, Neha
    Cashen, Amanda F.
    Gao, Feng
    Conradi, Kyle
    Rock, Amy D.
    Jeng, Emily K.
    Hernandez, Liza
    Egan, Jack O.
    Rhode, Peter R.
    Wong, Hing C.
    CANCER RESEARCH, 2018, 78 (13)
  • [35] The human IL-15 superagonist complex ALT-803 activates NK and memory T cells, reactivates latent SIV, and drives SIV-specific CD8+ T cells into B cell follicles
    Webb, Gabriela
    Hammond, Katherine
    Li, Shengbin
    Mwakalundwa, Gwantwa
    Greene, Justin
    Reed, Jason
    Stanton, Jeffrey
    Legasse, Alfred
    Park, Byung
    Axthelm, Michael
    Jeng, Emily
    Wong, Hing
    Whitney, James
    Jones, Brad
    Nixon, Douglas
    Skinner, Pamela
    Sacha, Jonah
    JOURNAL OF MEDICAL PRIMATOLOGY, 2018, 47 (05) : 307 - 307
  • [36] IL-15 has innate anti-tumor activity independent of NK and CD8 T cells
    Davies, Elizabeth
    Reid, Sarah
    Medina, Maria Fe
    Lichty, Brian
    Ashkar, Ali A.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2010, 88 (03) : 529 - 536
  • [37] Significantly targeting rituximab resistant B-cell lymphoma (BL) by anti-CD20 chimeric antigen receptor (CAR) modified expanded natural killer (NK) cells.
    Chu, Yaya
    Ayello, Janet
    Yahr, Ashlin
    Katz, Jared
    Lo, Lowrence
    Flowers, Allyson
    Cairo, Mitchell S.
    CANCER RESEARCH, 2013, 73
  • [38] The human IL-15 superagonist ALT-803 activates NK and memory T cells, reactivates latent SIV and drives SIV-specific CD8+T cells into B-cell follicles
    Webb, G.
    Li, S.
    Greene, J.
    Reed, J.
    Stanton, J.
    Legasse, A.
    Park, B.
    Axthelm, M.
    Jeng, E.
    Wong, H.
    Whitney, J.
    Jones, B.
    Nixon, D.
    Skinner, P.
    Sacha, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 80 - 80
  • [39] 'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy
    Miller, Jeffrey S.
    Cooley, Sarah
    Holtan, Shernan
    Arora, Mukta
    Ustun, Celalettin
    Jeng, Emily
    Wong, Hing C.
    Verneris, Michael R.
    Wagner, John E.
    Weisdorf, Daniel J.
    Blazar, Bruce R.
    Fehniger, Todd A.
    Romee, Rizwan
    BLOOD, 2015, 126 (23)
  • [40] Off-the-Shelf CAR-NK cells engineered to express calibrated release IL-15 exhibit enhanced persistence and anti-tumor activities
    Lee, Chen-Ting
    Hung, Michelle
    Banicki, Andrew
    Song, Wenqi
    Almudhfar, Niran
    Kaveri, Deepika
    Wong, Priscilla
    Naitmazi, Lawrence
    Guzman, Marcela
    Lam, Alice
    Yucel, Gozde
    Lu, Timothy
    Junca, Alba G.
    Garrison, Brian
    Lee, Philip
    CANCER RESEARCH, 2023, 83 (07)
12345